Roche’s blockbuster breast cancer treatment Herceptin will face more competition after Pfizer’s biosimilar won FDA approval March 11, according to Reuters. The FDA has already approved ...

Nov 30 (Reuters) - Pfizer Inc said on Wednesday its experimental biosimilar of Roche Holding AG's blockbuster breast cancer treatment Herceptin met the main goal in a key study. Pfizer tested the ...

The U.S. Food and Drug Administration said on Monday it approved Pfizer Inc's biosimilar to Roche AG's blockbuster treatment for breast cancer, Herceptin.

These three are biosimilars for Herceptin (trastuzumab), Avastin (bevacizumab), and Rituxan (rituximab). Separetly Pfizer is working on a biosimilar for Humira (adalimumab) and Remicade ...

Accord BioPharma, the speciality division of Intas Pharmaceuticals, has received US Food and Drug Administration (FDA) approval for 420mg HERCESSI (trastuzumab-strf), a biosimilar to reference ...

Approval of Accord’s Trastuzumab Biosimilar: On September 18, 2024, Accord announced that the Food and Drug Administration (FDA) approved a 420 mg dosage of HERCESSI (trastuzumab-strf), a ...